{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.9","upperLimit":"88.9","value":"62.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The primary endpoint will be the 2-year progression-free percent and will be reported with corresponding 90% confidence interval. All patients who have received one dose of study treatment will be included for the analysis, including those who die or are lost to follow-up before 2 years. Progression is defined as ≥ 25% increase and an absolute increase of ≥ 0.5g/dL from their nadir in their serum or urine m-spike or FLC with no CRAB features attributable to MM progression.","dispersionType":"90% Confidence Interval","groups":[{"description":"* A treatment cycle is defined as 28 consecutive days.\n* Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months.\n\nNivolumab: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and\n\nLenalidomide: Oral, predetermined dosage, Days 1-21 of cycle 1-12\n\nDexamethasone: Oral, Days 1, 8, 15 of cycle 1-6","id":"OG000","title":"Nivolumab, Lenalidomide, Dexamethasone"}],"paramType":"NUMBER","populationDescription":"All patients receiving any amount of protocol treatment. Patients who have progressed or lost to follow-up prior to two years are counted as failures; only patients followed and progression-free for at least two years are counted as successes.","reportingStatus":"POSTED","timeFrame":"2 Year","title":"2 Year Progression Free Percent","type":"PRIMARY","unitOfMeasure":"percentage of participants"}